Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dl-3-butylphthalide for amyotrophic lateral sclerosis
ChiCTR-IPR-15007365Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of butylphthalide in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: ALS Functional Rating Scale-Revised. Started Aug 2015; status: recruiting.
02
Drugs
butylphthalide
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR-IPR-15007365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007365.